Simplified process for the production of anti–CD19-CAR–engineered T cells

• Published in: Cytotherapy (Oxford, England) Vol. 15; no. 11; pp. 1406 - 1415
• Main Authors: Tumaini, Barbara, Lee, Daniel W., Lin, Tasha, Castiello, Luciano, Stroncek, David F., Mackall, Crystal, Wayne, Alan, Sabatino, Marianna
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.11.2013
• Subjects: adoptive cellular immunotherapy; Advanced Basic Science; Antigens, CD19 - immunology; CD19 antigen; CD28 Antigens - immunology; CD3 Complex - immunology; Cell Engineering - methods; Cells, Cultured; Cytotoxicity, Immunologic - genetics; Cytotoxicity, Immunologic - immunology; genetic engineering; genetic transduction; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell - immunology; Leukocytes, Mononuclear - cytology; Lymphocyte Activation - immunology; Other; precursor cell lymphoblastic leukemia-lymphoma; Receptors, Antigen - genetics; T-Lymphocytes - immunology; Transduction, Genetic; genetic transduction; adoptive cellular immunotherapy; CD19 antigen; precursor cell lymphoblastic leukemia-lymphoma; genetic engineering

Adoptive immunotherapy with the use of chimeric antigen receptor (CAR)-engineered T cells specific for CD19 has shown promising results for the treatment of B-cell lymphomas and leukemia. This therapy involves the transduction of autologous T cells with a viral vector and the subsequent cell expansi...